Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P04746

UPID:
AMYP_HUMAN

ALTERNATIVE NAMES:
1,4-alpha-D-glucan glucanohydrolase

ALTERNATIVE UPACC:
P04746; B9EJG1; Q9UBH3

BACKGROUND:
The enzyme Pancreatic alpha-amylase, known alternatively as 1,4-alpha-D-glucan glucanohydrolase, is integral to the human digestive process, catalyzing the hydrolysis of starch into simpler sugars. This action is vital for the metabolism of carbohydrates, facilitating the body's conversion of food into usable energy.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Pancreatic alpha-amylase unveils opportunities for innovative therapeutic interventions. Given its central role in carbohydrate metabolism, targeting this enzyme could lead to novel approaches in the treatment and management of conditions related to sugar metabolism, such as diabetes and obesity.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.